COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

https://www.immuneoncia.com/immun/

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Dec 5, 2022

ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia

Dec 27, 2021

WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody

Dec 24, 2021

CD47 Targeting Therapeutics Market Global Forecasts, 2021-2035, Featuring Abpro, Apmonia Therapeutics, Bristol Myers Squibb, ImmuneOncia Therapeutics and KAHR Medical

Mar 30, 2021

ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China

Jul 15, 2020

Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement

For More Press Releases

---